[go: up one dir, main page]

WO2011156729A3 - Methods of mitigating effects of radiation and reducing the risk of systemic infection - Google Patents

Methods of mitigating effects of radiation and reducing the risk of systemic infection Download PDF

Info

Publication number
WO2011156729A3
WO2011156729A3 PCT/US2011/040006 US2011040006W WO2011156729A3 WO 2011156729 A3 WO2011156729 A3 WO 2011156729A3 US 2011040006 W US2011040006 W US 2011040006W WO 2011156729 A3 WO2011156729 A3 WO 2011156729A3
Authority
WO
WIPO (PCT)
Prior art keywords
radiation
methods
reducing
subject
exposed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/040006
Other languages
French (fr)
Other versions
WO2011156729A2 (en
Inventor
Carney Darrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to CA2802176A priority Critical patent/CA2802176A1/en
Priority to AU2011265228A priority patent/AU2011265228A1/en
Priority to JP2013514392A priority patent/JP2013529600A/en
Priority to EP11728735.9A priority patent/EP2579891A2/en
Publication of WO2011156729A2 publication Critical patent/WO2011156729A2/en
Publication of WO2011156729A3 publication Critical patent/WO2011156729A3/en
Priority to US13/711,291 priority patent/US20130101574A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to methods of reducing mortality in a subject exposed to a lethal dose of radiation comprising administering to the subject an effective amount of a thrombin peptide derivative described herein. Also included are methods of reducing the risk of developing bacterial, fungal or viral systemic infection a subject who is exposed or not exposed to radiation, methods of treating a subject with traumatic injury, dermal injury and/or bum injury who is also exposed to radiation, methods of reducing radiation related injury in a subject undergoing radiation therapy, methods of reducing the risk of developing a radiation induced illness, and methods of promoting the healing of a wound that is caused by radiation exposure and/or has been exposed to radiation. These methods comprising administering to the subject an effective amount of a thrombin peptide derivative described herein.
PCT/US2011/040006 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection Ceased WO2011156729A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2802176A CA2802176A1 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection
AU2011265228A AU2011265228A1 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection
JP2013514392A JP2013529600A (en) 2010-06-11 2011-06-10 How to reduce the effects of radiation and reduce the risk of systemic infection
EP11728735.9A EP2579891A2 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection
US13/711,291 US20130101574A1 (en) 2010-06-11 2012-12-11 Methods of using thrombin peptide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35406710P 2010-06-11 2010-06-11
US61/354,067 2010-06-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/711,291 Continuation-In-Part US20130101574A1 (en) 2010-06-11 2012-12-11 Methods of using thrombin peptide derivatives

Publications (2)

Publication Number Publication Date
WO2011156729A2 WO2011156729A2 (en) 2011-12-15
WO2011156729A3 true WO2011156729A3 (en) 2012-05-10

Family

ID=44533067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/040006 Ceased WO2011156729A2 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Country Status (5)

Country Link
EP (1) EP2579891A2 (en)
JP (1) JP2013529600A (en)
AU (1) AU2011265228A1 (en)
CA (1) CA2802176A1 (en)
WO (1) WO2011156729A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207411A1 (en) * 2020-04-07 2021-10-14 Chrysalis Biotherapeutics Tp508 acute therapy for patients with respiratory virus infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003151A2 (en) * 1986-10-31 1988-05-05 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
WO2008036387A2 (en) * 2006-09-22 2008-03-27 Orthologic Corp. Method of treating endothelial dysfunction
WO2008124172A1 (en) * 2007-04-10 2008-10-16 The Board Of Regents, The University Of Texas System Combination therapy for chronic dermal ulcers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539800B1 (en) 2002-07-02 2007-05-23 Orthologic Corp. Thrombin peptide derivative dimers
AU2003256343B2 (en) 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
US7294596B2 (en) 2005-03-14 2007-11-13 Diamorph Ceramic Ab Sintered ceramic material with improved properties and method for its manufacturing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003151A2 (en) * 1986-10-31 1988-05-05 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
WO2008036387A2 (en) * 2006-09-22 2008-03-27 Orthologic Corp. Method of treating endothelial dysfunction
WO2008124172A1 (en) * 2007-04-10 2008-10-16 The Board Of Regents, The University Of Texas System Combination therapy for chronic dermal ulcers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2579891A2 *

Also Published As

Publication number Publication date
EP2579891A2 (en) 2013-04-17
JP2013529600A (en) 2013-07-22
WO2011156729A2 (en) 2011-12-15
CA2802176A1 (en) 2011-12-15
AU2011265228A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112015027282A2 (en) fenfluramine for use in the treatment of dravet syndrome
WO2012045090A3 (en) Therapeutic use of a tlr agonist and combination therapy
MX372883B (en) USE OF ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER.
EA201290846A1 (en) RADIOT THERAPY COMBINED WITH HYPOXIC CELL SENSITIZERS
WO2012093258A3 (en) Irf5- related treatment and screening
MX369385B (en) Products for healing of tissue wounds.
IN2015DN00450A (en)
IN2015DN00376A (en)
MX2015005798A (en) Combination therapy.
MX2014001050A (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate.
MX365007B (en) USE OF LYSOSOMAL LIPASE ACID TO TREAT LYSOSOMAL ACID LIPASE DIFFICIENCY IN PATIENTS.
EA032439B9 (en) Compositions and methods for treating surface wounds
BR112016000335A8 (en) method of treatment of papulopustular rosacea, treatment of inflammatory lesions of papulopustular rosacea and use of a pharmaceutical composition
MX2012014521A (en) Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation.
WO2016090024A3 (en) Combination therapy for treatment of cancer
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
TR201008226A2 (en) An inhalation device containing capsules.
MX382776B (en) USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY.
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
EA201270747A1 (en) COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF THE RAS
RU2012112399A (en) COMPOSITION AND METHOD FOR RESTORING SKIN
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
CA2866819C (en) Method for treating inflammation
WO2011156729A3 (en) Methods of mitigating effects of radiation and reducing the risk of systemic infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11728735

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2802176

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013514392

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011728735

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011265228

Country of ref document: AU

Date of ref document: 20110610

Kind code of ref document: A